QuidelOrtho (QDEL) is back in focus after filing a shelf registration for up to 1,000,000 shares of common stock. This ESOP-related move puts potential equity issuance on investors' radar.
See our latest analysis for QuidelOrtho.
At a share price of US$18.24, QuidelOrtho has seen a 30-day share price return of 29.18% and a 90-day share price return of 43.51%, yet the year-to-date share price return is down 36.62% and the 3-year total shareholder return has declined 78.49%. This suggests that recent momentum is building off a much weaker longer term record as investors reassess dilution risk and growth prospects around the ESOP shelf registration and the recent CFO inducement grant.
If this kind of move has you looking beyond a single diagnostics stock, it could be a useful moment to scan for other healthcare-related opportunities using the 39 healthcare AI stocks
QuidelOrtho’s diagnostics platform spans labs, transfusion medicine, point of care and molecular testing. This breadth can look appealing compared with a roughly US$1.2b market cap and a recent ESOP related shelf filing. Does that setup actually translate into an attractive price today?
Most Popular Narrative: 11% Undervalued
With QuidelOrtho closing at $18.24 against a narrative fair value of $20.50, the current setup hinges on how its diagnostics franchise scales and what that implies for future earnings.
Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China, where differentiated technology, low market share, and a large runway for immunoassay growth exist, positions QuidelOrtho to capture increased demand stemming from global health system focus on early detection and public health surveillance, which should drive topline revenue growth.
Curious what has to happen inside QuidelOrtho for that valuation to make sense? The narrative leans on modest revenue growth, a sharp margin reset and a future earnings multiple you might not expect.
Result: Fair Value of $20.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the QuidelOrtho story still has pressure points, including weaker COVID testing revenue and product discontinuations that cut into diversification and potential future earnings.
Find out about the key risks to this QuidelOrtho narrative.
Next Steps
If the mixed tone around QuidelOrtho leaves you unsure, do not wait on others to decide for you. Instead, review the full balance of 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond QuidelOrtho?
If QuidelOrtho has sharpened your focus on where capital works hardest, this is the moment to line up a few more ideas you do not want to miss.
- Spot potential bargains early by scanning screener containing 20 high quality undiscovered gems that pair solid fundamentals with under-the-radar stories.
- Prioritise resilience by filtering for companies in the 82 resilient stocks with low risk scores that score well on business stability and risk controls.
- Sharpen your watchlist with the solid balance sheet and fundamentals stocks screener (48 results) to focus on businesses backed by healthier leverage and stronger financial footing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com